InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,985.38
(
0.02%
)
US TECH 100
20,500.00
(
0.05%
)
Dow Jones
43,958.19
(
0.11%
)
Brent Oil
72.13
(
0.36%
)
Bitcoin
91,227.61
(
0.73%
)
Post# of 253594
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

dav1234

Send PM Follow Ignore
Followers 97
Posts 92809
Boards Moderated 4
Alias Born 10/29/2007

dav1234

Re: None

Tuesday, 11/19/2013 9:41:02 AM

Tuesday, November 19, 2013 9:41:02 AM

Post# of 253594



Committee recommends continuation of OncoGenex trial
The IDMC for OncoGenex Pharmaceuticals' (OGXI) Phase 3 study (SYNERGY) of a custirsen/first-line docetaxel combo in metastatic castrate-resistant prostate cancer recommends that the trial continue to final analysis.
Survival data is due in mid-2014
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up